文章：

免疫检查点抑制剂时代中性粒细胞在非小细胞肺癌中的多重作用

The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors

原文发布日期：10 July 2024

DOI: 10.3390/cancers16142507

类型: Article

开放获取: 是

英文摘要：

Lung cancer is the most common cause of cancer-related death in both males and females in the U.S. and non-small-cell lung cancer (NSCLC) accounts for 85%. Although the use of first- or second-line immune checkpoint inhibitors (ICIs) exhibits remarkable clinical benefits, resistance to ICIs develops over time and dampens the efficacy of ICIs in patients. Tumor-associated neutrophils (TANs) have an important role in modulating the tumor microenvironment (TME) and tumor immune response. The major challenge in the field is to characterize the TANs in NSCLC TME and understand the link between TAN-related immunosuppression with ICI treatment response. In this review, we summarize the current studies of neutrophil interaction with malignant cells, T-cells, and other components in the TME. Ongoing clinical trials are aimed at utilizing reagents that have putative effects on tumor-associated neutrophils, in combination with ICI. Elevated neutrophil populations and neutrophil-associated factors could be potential therapeutic targets to enhance anti-PD1 treatment in NSCLC.

摘要翻译： 

肺癌是美国男性和女性癌症相关死亡的最常见原因，其中非小细胞肺癌占85%。尽管一线或二线免疫检查点抑制剂的应用显示出显著的临床获益，但随着时间的推移会产生耐药性，从而削弱ICIs对患者的疗效。肿瘤相关中性粒细胞在调节肿瘤微环境和肿瘤免疫应答中具有重要作用。该领域的主要挑战在于明确非小细胞肺癌肿瘤微环境中TANs的特征，并理解TAN相关免疫抑制与ICI治疗反应之间的关联。本综述总结了当前关于中性粒细胞与肿瘤微环境中恶性细胞、T细胞及其他组分相互作用的研究。正在进行的临床试验旨在利用对肿瘤相关中性粒细胞具有推定效应的试剂与ICI联合治疗。升高的中性粒细胞群及中性粒细胞相关因子可能成为增强非小细胞肺癌抗PD1治疗的潜在治疗靶点。

原文链接：

The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors